Victoria Socha

DocwireNews

American Society of Transplant Surgeons Winter Symposium 2021To prevent rejection, recipients of organ transplants initiate a regimen of immunosuppressive medications. Modulation of immunosuppressants to prevent rejection is enabled via early detection of allograft injury. Kidney allograft rejection is indicated by elevated levels of donor-derived cell-free DNA (<a href="https://www.docwirenews.com/docwire-pick/monitoring-allograft-rejection-with-dd-cfdna-testing/">dd-cfDNA</a>). Multiple factors, including therapy, surgical trauma, and comorbidities, can influence total levels of dd-cfDNA.Prince Mohan, MD, at Geisinger Commonwealth Medical Hospital, Danville, Pennsylvania, and colleagues conducted a retrospective analysis of data from a patient with a biopsy confirmed antibody-mediated rejection who underwent serial blood draws for the assessment of dd-cfDNA. Results of the analysis were reported during a virtual <a href="https://asts.org/events-meetings/winter-symposium#.YEZRil1Kikp">poster</a> session at the American Society of Transplant Surgeons 21st Annual State of the Art Winter Symposium. The poster was titled Anti-Rejection Therapies in Renal Transplant Patients May Influence Total Cell-Free DNA, Impacting Relative Quantification of Donor-Derived Cell-Free DNA.The patient, a 52-year-old male, received a deceased donor kidney transplant in 2016. He was maintained on a triple immunosuppressive therapy regimen. His serum creatinine levels were stable, ranging from 1.4 to 1.6 mg/dL. At 4 years post-transplant, the patient presented with increased serum creatinine (2 mg/dL). Biopsy confirmed antibody-mediated rejection with moderate transplant glomerulopathy, and the patient was treated with plasmapheresis (1 gm/kg) and rituximab (1 gm). Following treatment, rejection was monitored with dd-cfDNA analysis on blood samples.Five months after the biopsy confirmed active rejection, the initial blood test showed elevated dd-cfDNA level of 4.67%. Total cfDNA level was within the normal range. One month later, a second blood test demonstrated a drop in dd-cfDNA fraction of 0.64%, with a total cfDNA level elevated 11.2 times above the median. Subsequent blood tests demonstrated increases in dd-cfDNA and decreases in total cfDNA levels.In conclusion, the researchers said, &ldquo;These findings suggest that increases in total cfDNA levels may confound interpretation of dd-cfDNA test results. This case suggests that antirejection therapies may influence total cfDNA levels. The findings highlight the importance of continued monitoring of both dd-cfDNA and total cfDNA levels in identifying a true response to therapy.&rdquo;Source: Mohan P, McCormick S, Wade H, et al. Anti-Rejection Therapies in Renal Transplant Patients May Influence Total Cell-Free DNA, Impacting the Relative Quantification of Donor-Derived Cell-Free DNA. Poster presented at the American Society of Transplant Surgeons virtual 21st Annual State of the Art Winter Symposium (E-poster 92), January 14, 2021. Support for this study was provided by Natera, Inc.

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

Anti-Rejection Therapies May Influence Total cfDNA Levels

Kidney Transplantation

American Society of Transplant Surgeons Winter Symposium 2021 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe